Biocon Limited has announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported robust performance across both standalone and consolidated statements. Key highlights include significant revenue from operations, improved profit before tax, and healthy net profit figures, indicating strong operational efficiency and market position.
Biocon Reports Strong Financial Performance for Q1 FY27
Biocon Limited has disclosed its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved these results on August 05, 2026, following a limited review by statutory auditors.
Standalone Financial Highlights
For the quarter ended June 30, 2026, Biocon’s standalone total income stood at ₹6,893 million, a notable increase from previous periods. The profit before tax was ₹699 million, and the net profit for the period was ₹522 million. Earnings per share (EPS) for the quarter were ₹0.32 on a basic and diluted basis.
Consolidated Financial Performance
On a consolidated basis, Biocon demonstrated even stronger growth. The total income for the quarter reached ₹43,905 million. The company reported a profit before tax of ₹1,411 million, and the profit for the period attributable to shareholders was ₹1,368 million. The consolidated EPS stood at ₹0.87 for basic and diluted.
Key Notes and Disclosures
The financial results have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The consolidated financial results encompass the financial performance of Biocon Limited and its numerous subsidiaries.
The statement also details various exceptional items and their impact, alongside notes on segment-wise performance, which collectively contribute to the company’s overall financial narrative for the quarter.
Source: BSE
